These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20127944)

  • 1. Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.
    Youssoufian H; Rowinsky EK; Tonra J; Li Y
    Cancer; 2010 Feb; 116(4 Suppl):1013-7. PubMed ID: 20127944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
    Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
    Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
    Piloto O; Levis M; Huso D; Li Y; Li H; Wang MN; Bassi R; Balderes P; Ludwig DL; Witte L; Zhu Z; Hicklin DJ; Small D
    Cancer Res; 2005 Feb; 65(4):1514-22. PubMed ID: 15735040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.
    Yamamoto Y; Tsuzuki S; Akahori Y; Ukai Y; Sumitomo M; Murayama Y; Yamamoto K; Inaguma Y; Tokuda M; Abe A; Akatsuka Y; Emi N; Kurosawa Y
    Cancer Sci; 2012 Feb; 103(2):350-9. PubMed ID: 22049994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigational drugs targeting FLT3 for leukemia.
    Ustun C; DeRemer DL; Jillella AP; Bhalla KN
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1445-56. PubMed ID: 19671038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
    Li Y; Li H; Wang MN; Lu D; Bassi R; Wu Y; Zhang H; Balderes P; Ludwig DL; Pytowski B; Kussie P; Piloto O; Small D; Bohlen P; Witte L; Zhu Z; Hicklin DJ
    Blood; 2004 Aug; 104(4):1137-44. PubMed ID: 15105287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
    Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
    Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3 inhibitors in acute myeloid leukemia.
    el-Shami K; Stone RM; Smith BD
    Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.
    Williams B; Atkins A; Zhang H; Lu D; Jimenez X; Li H; Wang MN; Ludwig D; Balderes P; Witte L; Li Y; Zhu Z
    Leukemia; 2005 Aug; 19(8):1432-8. PubMed ID: 15931264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 inhibition in acute myeloid leukaemia.
    Knapper S
    Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.
    Hofmann M; Große-Hovest L; Nübling T; Pyż E; Bamberg ML; Aulwurm S; Bühring HJ; Schwartz K; Haen SP; Schilbach K; Rammensee HG; Salih HR; Jung G
    Leukemia; 2012 Jun; 26(6):1228-37. PubMed ID: 22289926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
    Shabbir M; Stuart R
    Expert Opin Investig Drugs; 2010 Mar; 19(3):427-36. PubMed ID: 20141349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
    Giles FJ
    Leuk Res; 2006 Dec; 30(12):1469-70. PubMed ID: 16631251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
    Fesler MJ; Richart JM; Petruska PJ
    Leuk Res; 2010 Oct; 34(10):e268-9. PubMed ID: 20417967
    [No Abstract]   [Full Text] [Related]  

  • 16. Can FLT3 inhibitors overcome resistance in AML?
    Tam WF; Gary Gilliland D
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 antibody-based therapeutics for leukemia therapy.
    Li Y; Zhu Z
    Int J Hematol; 2005 Aug; 82(2):108-14. PubMed ID: 16146840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineoplastic effect of a single oral dose of the novel Flt3 inhibitor KRN383 on xenografted human leukemic cells harboring Flt3-activating mutations.
    Nishiyama U; Yoshino T; Ozai M; Yoshioka R; Fujisawa M; Ogasawara Y; Kitahori M; Yoshioka E; Kubo K; Komeno Y; Kurokawa M; Ogawa S; Chiba S; Osawa T; Kuwaki T; Hirai H; Miwa A
    Leuk Res; 2006 Dec; 30(12):1541-6. PubMed ID: 16603240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lestaurtinib: a multi-targeted FLT3 inhibitor.
    Fathi AT; Levis M
    Expert Rev Hematol; 2009 Feb; 2(1):17-26. PubMed ID: 21082990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A substrate peptide for the FLT3 receptor tyrosine kinase.
    Böhmer FD; Uecker A
    Br J Haematol; 2009 Jan; 144(1):127-30. PubMed ID: 19016738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.